Material
Synthetic investigational peptide
Metabolic research
Retatrutide40 MG
Retatrutide is an investigational GLP-1, GIP and glucagon receptor agonist studied in metabolic research.
Product code RT040
MaterialSynthetic investigational peptide
Research contextMulti-receptor metabolic peptide research.
Veyvanta / profile
Compound profile
* Vial labels may use shortened names to keep the label legible. The full material and composition are stated in this profile.
Composition
Single peptide material; salt and excipient form are batch-specific.
Research context
Multi-receptor metabolic peptide research.
Research interest
Why it draws attention
Retatrutide is one of the most closely watched metabolic research peptides because one molecule engages the GIP, GLP-1, and glucagon receptor pathways.
Signals researchers are following
- 01
GIP, GLP-1, and glucagon receptor signaling
- 02
Body-weight, glycemic, and broader metabolic endpoints
Evidence levelHuman clinical evidence
Published evidence / research profile
What the published research shows
A source-led view of the findings reported to date, the maturity of the evidence, and the limits that matter when interpreting it.
Evidence levelHuman clinical evidence
Common research directions
- GIP, GLP-1, and glucagon receptor signaling
- Body-weight, glycemic, and broader metabolic endpoints
Reported findings
Research now includes Phase 3 TRIUMPH results alongside earlier randomized studies of body-weight and glycemic endpoints. The TRIUMPH-1 obesity study was published in September 2026. Findings vary with the population and analysis; gastrointestinal adverse events and tolerability remain important to interpretation.
How to read the evidence
Retatrutide remains investigational despite its advancing clinical program. Findings from controlled trials of sponsor-manufactured material do not establish the identity, equivalence, safety, or performance of a research vial.
Selected references
Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of ObesityN Engl J Med (2026)View sourceTRIUMPH-2 Phase 3 Detailed ResultsLilly sponsor disclosure (September 2026)View sourceRetatrutide in Metabolic Dysfunction-Associated Steatotic Liver DiseaseNat Med (2024)View sourceTriple-Hormone-Receptor Agonist Retatrutide for ObesityN Engl J Med (2023)View sourceRetatrutide for People With Type 2 DiabetesLancet (2023)View source
This summary describes published research on the named material or its components. It does not establish safety, efficacy, equivalence, or suitability of this Veyvanta research product for human use.
Lab math
Reconstitution & measurement calculator
Convert a declared vial amount and diluent volume into nominal concentration, liquid volume, and the equivalent position on a U-100 scale.
Research product
Research productRetatrutide / 40 MG
Calculation basisRetatrutide
Calculated measurement
Enter a positive diluent volume and target amount to calculate.
A calculation, not a protocol
This tool performs unit conversion only. It does not recommend an amount, frequency, route, diluent, handling method, or human use. Results assume ideal mixing and a U-100 scale of 100 units per mL; validated laboratory procedures and material-specific compatibility take priority.
Product & historical codes
Current batch record
The product code identifies this material and declared strength. Supplier lot, expiry and analytical documentation are recorded separately when available.
- Batch
- RT641
- Expiry
- 1/6/28
Veyvanta internal batch record.
Find a label code
Direct product QR
This permanent link opens this exact product and strength. It does not certify an individual vial.
veyvanta.com/p/RT040Metabolic research
